# US 2015/0086576 A1 · Sortase-modified vhh domains and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0086576 A1
- Document ID: US20150086576A1
- Status: Published application
- Kind: A1
- Application number: 14/394,046
- Filed: 2013-04-15
- Published: 2015-03-26
- Earliest claimed: 2012-04-13
- Assignees: Whitehead Institute for Biomedical Research
- Applicants: Whitehead Institute for Biomedical Research
- Inventors: Hidde Ploegh; Maximilian Popp; Juanjo Cragnolini
- Web page: https://patentgrep.com/patent/US20150086576A1

## CPC

- C07K 16/2833: {against MHC-molecules, e.g. HLA-molecules}
- A61K 47/6849: {the antibody targeting a receptor, a cell surface antigen or a cell surface determinant}
- A61K 47/6851: {the antibody targeting a determinant of a tumour cell}
- A61P 37/02: Immunomodulators
- C07K 1/13: Labelling of peptides
- C07K 16/108: Orthomyxoviridae (F), e.g. influenza virus
- C07K 16/44: against material not provided for elsewhere {, e.g. haptens, metals, DNA, RNA, amino acids}
- C07K 16/468: {Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies}
- C12N 9/52: derived from bacteria {or Archaea}
- G01N 33/582: {with fluorescent label}
- A61K 2039/505: {comprising antibodies}
- C07K 2317/22: from camelids, e.g. camel, llama or dromedary
- C07K 2317/569: Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
- C07K 2319/90: containing a motif for post-translational modification
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

In some aspects, polypeptides comprising single domain antibodies and methods of identifying single domain antibodies are provided. In some embodiments polypeptides comprising a single domain antibody and a sortase recognition sequence, are provided. In some aspects, products and methods of use in modulating the immune system, e.g., modulating an immune response, are provided.

## Claims

### Claim at position 1

1-120. (canceled)

### Claim 121

A polypeptide comprising a VHH domain, wherein the VHH domain binds to an MHC Class II complex.

### Claim 122 (depends on 121)

The polypeptide of claim 121, further comprising a moiety that is attached to the polypeptide.

### Claim 123 (depends on 121)

The polypeptide of claim 121, further comprising a moiety that is attached to the polypeptide, wherein the moiety comprises an amino acid, a peptide, a protein, a polynucleotide, a carbohydrate, a tag, a metal atom, a chelating agent, a contrast agent, a catalyst, a polymer, a recognition element, a small molecule, a lipid, a label, an epitope, a small molecule, a therapeutic agent, a cross-linker, a toxin, a radioisotope, an antigen, or a click chemistry handle.

### Claim 124 (depends on 121)

The polypeptide of claim 121, further comprising a transamidase recognition sequence.

### Claim 125 (depends on 121)

The polypeptide of claim 121, further comprising a transamidase recognition sequence and a moiety that is attached to the transamidase recognition sequence.

### Claim 126 (depends on 125)

The polypeptide of claim 125, wherein the polypeptide comprises VHH7 or an antigen-binding fragment thereof or competes with VHH7 for binding to an MHC Class II complex protein, or wherein the polypeptide comprises VHH4 or an antigen-binding fragment thereof or competes with VHH4 for binding to an MHC Class II complex protein.

### Claim 127 (depends on 125)

The polypeptide of claim 125, wherein the VHH domain comprises the complementarity determining regions of VHH7, or wherein the VHH domain comprises the complementarity determining regions of VHH4.

### Claim 128 (depends on 125)

A method of delivering a moiety to an immune system cell comprising contacting the immune system cell with the polypeptide of claim 125.

### Claim 129 (depends on 125)

A method of delivering a moiety to an immune system cell in a subject, wherein the immune system cell expresses an MHC Class II complex at its surface, the method comprising administering the polypeptide of claim 125 to the subject.

### Claim 130 (depends on 125)

A method of modulating the immune system of a subject, the method comprising administering the polypeptide of claim 125 to the subject.

### Claim 131 (depends on 130)

The method of claim 130, wherein the moiety comprises an epitope, and modulating the immune system comprises modulating the response of the immune system to the epitope.

### Claim 132 (depends on 121)

The polypeptide of claim 121, further comprising a transamidase recognition sequence and a moiety that is attached to the transamidase recognition sequence, wherein the moiety comprises an amino acid, a peptide, a protein, a polynucleotide, a carbohydrate, a tag, a metal atom, a chelating agent, a contrast agent, a catalyst, a polymer, a recognition element, a small molecule, a lipid, a label, an epitope, a small molecule, a therapeutic agent, a cross-linker, a toxin, a radioisotope, an antigen, or a click chemistry handle.

### Claim 133 (depends on 132)

The polypeptide of claim 132, wherein the moiety comprises a radioisotope.

### Claim 134 (depends on 121)

The polypeptide of any of claim 121, further comprising a transamidase recognition sequence and a moiety that is attached to the transamidase recognition sequence, wherein the moiety comprises an epitope that originates from a pathogen or tumor.

### Claim 135 (depends on 121)

The polypeptide of claim 121, wherein the polypeptide comprises VHH7 or an antigen-binding fragment thereof or competes with VHH7 for binding to an MHC Class II complex protein, or wherein the polypeptide comprises VHH4 or an antigen-binding fragment thereof or competes with VHH4 for binding to an MHC Class II complex protein.

### Claim 136 (depends on 135)

A method of delivering a moiety to an immune system cell comprising contacting the immune system cell with the polypeptide of claim 135.

### Claim 137 (depends on 135)

A method of delivering a moiety to an immune system cell in a subject, wherein the immune system cell expresses an MHC Class II complex at its surface, the method comprising administering the polypeptide of claim 135 to the subject.

### Claim 138 (depends on 135)

A method of modulating the immune system of a subject, the method comprising administering the polypeptide of claim 135 to the subject.

### Claim 139 (depends on 121)

The polypeptide of claim 121, wherein the VHH domain comprises the complementarity determining regions of VHH7, or wherein the VHH domain comprises the complementarity determining regions of VHH4.

### Claim 140

An agent comprising (a) a targeting moiety A that binds to an MHCII complex; and (b) an antigen B, wherein A and B are physically associated with each other.

### Claim 141 (depends on 140)

The agent of claim 140, wherein the targeting moiety A comprises an antibody, an antibody chain, an antibody fragment, an scFv, a VHH domain, a single-domain antibody, an adnectin, or an aptamer, that binds to an MHCII complex.

### Claim 142 (depends on 140)

A composition comprising the agent of claim 140 and an adjuvant.

### Claim 143 (depends on 140)

A method of modulating the immune response of a subject to an antigen, the method comprising administering the agent of claim 140 or a composition comprising the agent and an adjuvant to the subject.

### Claim 144 (depends on 140)

A method of treating a subject in need of treatment for an infection or tumor, the method comprising administering the agent of claim 140 or a composition comprising the agent and an adjuvant to the subject, wherein the antigen comprises a pathogen-derived antigen or tumor antigen.

### Claim 145 (depends on 144)

The method of claim 144, wherein the targeting moiety binds to a human MHCII complex and the cell or subject is human.
